Management of statin intolerance in 2018: still more questions than answers

PP Toth, AM Patti, RV Giglio, D Nikolic… - American Journal of …, 2018 - Springer
Statin therapy is generally well tolerated and very effective in the prevention and treatment of
cardiovascular disease, regardless of cholesterol levels; however, it can be associated with …

Statin non-adherence and residual cardiovascular risk: there is need for substantial improvement

M Banach, T Stulc, R Dent, PP Toth - International journal of cardiology, 2016 - Elsevier
Although statin therapy has proven to be the cornerstone for prevention and treatment of
cardiovascular disease (CVD), there are many patients for whom long-term therapy remains …

American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of dyslipidemia and prevention of …

PS Jellinger, Y Handelsman, PD Rosenblit… - Endocrine Practice, 2017 - Elsevier
Objective The development of these guidelines is mandated by the American Association of
Clinical Endocrinologists (AACE) Board of Directors and American College of Endocrinology …

Cardiovascular risk and dyslipidemia among persons living with HIV: a review

P Maggi, A Di Biagio, S Rusconi, S Cicalini… - BMC infectious …, 2017 - Springer
Background Aim of this review is to focus the attention on people living with HIV infection at
risk of developing a cardiovascular event. What is or what would be the most suitable …

[HTML][HTML] Cardiac autonomic neuropathy: Risk factors, diagnosis and treatment

VA Serhiyenko, AA Serhiyenko - World journal of diabetes, 2018 - ncbi.nlm.nih.gov
Cardiac autonomic neuropathy (CAN) is a serious complication of diabetes mellitus (DM)
that is strongly associated with approximately five-fold increased risk of cardiovascular …

Effects of PCSK9 targeting: alleviating oxidation, inflammation, and atherosclerosis

E Punch, J Klein, P Diaba‐Nuhoho… - Journal of the …, 2022 - Am Heart Assoc
Characterized as a chronic inflammatory disease of the large arteries, atherosclerosis is the
primary cause of cardiovascular disease, the leading contributor of morbidity and mortality …

Therapeutic RNA-silencing oligonucleotides in metabolic diseases

A Goga, M Stoffel - Nature Reviews Drug Discovery, 2022 - nature.com
Recent years have seen unprecedented activity in the development of RNA-silencing
oligonucleotide therapeutics for metabolic diseases. Improved oligonucleotide design and …

The effect of chronic kidney disease on lipid metabolism

N Dincer, T Dagel, B Afsar, A Covic, A Ortiz… - … Urology and Nephrology, 2019 - Springer
The major cause of death among chronic kidney disease patients is cardiovascular
diseases. Cardiovascular and kidney disease are interrelated and increase the severity of …

[HTML][HTML] New perspectives on atherogenic dyslipidaemia and cardiovascular disease

AJ Lorenzatti, PP Toth - European Cardiology Review, 2020 - ncbi.nlm.nih.gov
Over the past few decades, atherogenic dyslipidaemia has become one of the most common
phenotypic presentations of lipid abnormalities, being strongly and unequivocally …

Future perspectives of the pharmacological management of diabetic dyslipidemia

AM Patti, RV Giglio, N Papanas, M Rizzo… - Expert Review of …, 2019 - Taylor & Francis
Introduction: Diabetic dyslipidemia is frequent among patients with type 2 diabetes mellitus
(T2DM) and is characterized by an increase in triglycerides (TGs), low-density lipoprotein …